In so doing, they seem to follow Briggs et al. 7 who speculated that BM suppression, perhaps sometimes progressing to aplastic anemia, might be part of the CRMCC phenotype and that Revesz syndrome might thus be the same as CRMCC, or an allelic variant.
We would like to emphasize differences between these two syndromes, which we believe are distinct, although both may be characterized by intrauterine growth retardation, bilateral exudative retinopathy, intracranial calcifications and cysts, leukoencephalopathy and, in some cases, sparse hair, nail dystrophy and cutaneous changes.
First, although about one third of patients with CRMCC have hypochromic microcytic to macrocytic or normochromic normocytic anemia, which may require blood transfusions, 2,7 aplastic anemia necessitating BMT is typical of Revesz syndrome 3, 4, 8 and thus far has never been described in CRMCC. Instead, even increased erythropoiesis has sometimes been reported. 2 Thrombocytopenia, which has resolved after splenectomy, may also occur. 2 Major intestinal bleeding, not reported in Revesz syndrome, contributes to anemia in CRMCC. 2, 7 Moreover, patients with CRMCC have skeletal abnormalities not characteristic of Revesz syndrome, 2, 7 and the intrauterine growth retardation in CRMCC is more pronounced than in Revesz syndrome. The birth weight in CRMCC ranges from À 1.8 to À 4.0 (median À 3.5) s.d. These two syndromes are also distinct genetically. Mutations associated with Revesz syndrome have thus far been limited to autosomal dominant TINF2 mutations in codons 280 and 282, although not all such mutations lead to this phenotype. 1, [4] [5] [6] In contrast, patients with CRMCC have recently been shown to harbor compound heterozygous autosomal recessive mutations in CTC1, encoding the CTS telomere maintenance complex component 1.
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TINF2 encodes TIN2, one of the key components of shelterin, a protein complex that stabilizes telomeres. 4 The related function of these two different genes probably underlies the significantly overlapping but distinct phenotypes.
On the basis of the characteristic TINF2 mutation, the patient of Asai et al.
1 has Revesz syndrome and not CRMCC. The diagnosis of patients reported to have Revesz syndrome with milder hematological abnormalities than aplastic anemia in the absence of cerebellar hypoplasia will remain open without genetic proof.
Asai et al. 1 recommended HSCT using a fludarabine-based reduced-intensity conditioning for treatment of what they thought were CRMCC patients with hematological disorders. As fatal intestinal bleeding occurs in patients with true CRMCC, 2, 9 their hematological problems do not progress to aplastic anemia and they have no clonal chromosome changes in BM, caution should be exercised before considering HSCT in CRMCC.
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